• Research

    New Paper from Finland – Altered linkage pattern of N-glycan sialic acids in PMP

    All human cells are covered by sugar coating, mostly consisting of glycan structures attached to proteins and lipids, and this coating frequently shows alterations in tumor cells. In their new publication, Finland’s Pirjo Nummela, Anna Lepistö and Ari Ristimäki have analyzed the profiles of a specific class of glycans, sialylated N-glycans, in PMP tissues compared to both normal appendices and the original appendix tumors (LAMNs). According to their results, PMPs present increased expression of glycans able to function as ligands of Siglecs and selectins, which may play a role in the peritoneal dissemination and progression of the disease. Further, the glycan profiles of PMPs suggest that the process of its…

  • Research

    Incidence and Prevalence in Europe

    EuroPMP member researchers from Norway and the United Kingdom have recently published a paper giving a sound scientific footing for the incidence and prevalence of PMP in Europe. The research suggests that the previous incidence estimate of 1-2 persons per million is too low, with a more realistic figure being around 3.2 persons per million. The prevalence was estimated to be around 22 persons per million in Europe, meaning 11,726 people living with active disease in 2018. The incidence and prevalence paper can be read here.  

  • News

    The Effects of COVID-19 on PMP Services Around Europe

    Around the world, the COVID-19 epidemic has been hitting our health care systems very hard. Intensive care units have been inundated with patients requiring careful, around-the-clock care. Physicians have been transferred from their normal duties to hastily set up critical care wards within their districts to try to treat the vast numbers of affected patients. Nurses have been sent out to test patients in temporary drive-up clinics, and biologists and lab workers have had their normal duties re-directed to include testing the enormous numbers of patient samples incoming daily from worried patients. We have heard much about the effects on primary care physicians and clinical specialists, but we have not…

  • Research

    Individual Efficacy of Drug Therapies in Xenograft Models

    Norway’s Karianne Giller Fleten, Christin Lund-Andersen, Annette Torgunrud and Kjersti Flatmark have published a new paper that looks into the individual efficacy of four drug therapies on peritoneal metastases in mouse-human xenograft models: oxaliplatin, irinotecan, cabazitaxel, and regorafenib and capecitabine. The results support the continued exploration of intraperitoneal treatment protocols for peritoneal metastases with oxaliplatin remaining and cabazitaxel emerging as the most interesting candidates for further studies. You can read the new paper here.

  • News

    PSOGI/EURACAN Clinical Practice Guidelines

    A new consensus paper undertaking a complex and thorough investigation into current clinical practice has been released by an international group including many members of EuroPMP. As pseudomyxoma peritonei (PMP) is such a rare disease, it is difficult to find large, randomised trials on which to base treatment decisions. Therefore, using the Delphi consensus model, the Peritoneal Surface Oncology Group International (PSOGI) Executive Committe, which includes may members of EuroPMP, have examined and recommended a new and current best practice for the diagnosis and treatment of PMP. The Delphi decision model was used in conjunction with a broad literature review to come to this agreement, which will now form a…

  • News

    COST Advisory – COVID-19 Outbreak (updated)

    Updated 22 April 2020 at 19:00 (Originally published on 2nd February 2020 at 11:23am) New Information The COST Association has now asked that all face-to-face meetings, STSMs and training schools be cancelled until at least the 30th of April. The use of videoconferencing and other means of communication are recommended. The COST notice may be viewed here.   Previous Information The COST Association has released an advisory note about international travel in the context of the current coronavirus (COVID-19) outbreak. COST has examined the advice of the World Health Organisation (WHO) and national governmental bodies, and has determined that, for the present, international travel does not need to be limited…

  • News

    Twenty-Three Countries Now Acting on PMP

    Since the beginning of the EuroPMP COST Action about 1.5 years ago, the Action has included researchers from many countries, not just in Europe, but around the world. The number of countries now taking part in the action has doubled in the past year alone, and now includes partners from over 23 countries including  Azerbaijan, Bosnia and Herzegovina, Belgium, Germany, Greece, Spain, Finland, France, Croatia, North Macedonia, Ireland, Israel, Italy, Latvia, Montenegro, Norway, Pakistan, Poland, Portugal, Romania, Sweden, Turkey and the United Kingdom. The EuroPMP COST Action aims to increase cooperation between researchers across Europe and around the world to improve research into the cause, detection and treatment of Pseudomyxoma…

  • Events

    Rescheduling of the PMP Workshop

    Save the date! In light of the continuing issues around the COVID-19 pandemic, it has not been possible to reschedule the Pathology Workshop for the near future. Therefore, the Core Committee has proposed a new date of the 10-11th December 2020 for the PMP Pathology Workshop in Basingstoke. As before, the Core Committee will send information to all EuroPMP members closer to the date. If the COVID-19 pandemic has not resolved by this time, the Core Committee may need to reschedule to an even later date. We remain hopeful, however, that the medical emergency will have subsided by December, and so we ask all pathology-interested members to block the time…

  • News

    NORD ACPMP Award for Flatmark Lab

    Prof Kjersti Flatmark’s research group in Oslo have been awarded a NORD ACPMP Research Grant (ID: 19010) to look into the identification of biomarkers in the blood stream of patients. The title of the study is “ctDNA for monitoring patients with pseudomyxoma peritonei”. Pseudomyxoma peritonei (PMP) is a rare abdominal cancer that exhibits specific DNA mutations. After treatment by surgery and intraperitoneal chemotherapy, radiological follow-up has low sensitivity and specificity for detecting disease recurrence. Mutations may be detectible in blood samples, and in this project we will establish and test a method for analyzing circulating tumor DNA (ctDNA) from patients with PMP before and after surgery. If successful, this method…

  • News

    New STSM to Oslo

    Yaroslaw Sautkin, a EuroPMP member from Germany, has completed a Short-Term Scientific Mission to Professor Kjersti Flatmark’s Translational Cancer Therapy lab at Oslo University Hospital’s Institute for Cancer Research. While on his STSM, Yaroslaw learned more about the use of experimental animal models for pseudomyxoma peritonei (PMP) in order to further the work that his own institution, the University of Tübingen, is undertaking into the use of PIPAC with mucolytic substances. Yaroslaw’s visit allowed members of both teams to meet and share knowledge, leading to stronger synergies between their researchers. Both groups are now looking forward to working on research projects together in the future. STSMs are offered several times…